stoxline Quote Chart Rank Option Currency Glossary
  
Cerus Corporation (CERS)
1.37  0 (0%)    04-23 16:00
Open: 1.4069
High: 1.48
Volume: 1,011,483
  
Pre. Close: 1.37
Low: 1.355
Market Cap: 255(M)
Technical analysis
2025-04-23 4:37:51 PM
Short term     
Mid term     
Targets 6-month :  1.85 1-year :  2.16
Resists First :  1.59 Second :  1.85
Pivot price 1.31
Supports First :  1.29 Second :  1.12
MAs MA(5) :  1.32 MA(20) :  1.33
MA(100) :  1.62 MA(250) :  1.79
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  69 D(3) :  61.9
RSI RSI(14): 48.7
52-week High :  2.53 Low :  1.12
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CERS ] has closed below upper band by 26.7%. Bollinger Bands are 32.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.48 - 1.49 1.49 - 1.5
Low: 1.34 - 1.35 1.35 - 1.35
Close: 1.36 - 1.37 1.37 - 1.38
Company Description

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

Headline News

Thu, 17 Apr 2025
Cerus Corporation to Release First Quarter 2025 Financial Results on May 1, 2025 | CERS Stock News - GuruFocus

Thu, 17 Apr 2025
Cerus Corporation to Release First Quarter 2025 Financial Results on May 1, 2025 - Business Wire

Thu, 17 Apr 2025
Cerus Corporation Sets Date for Q1 2025 Financial Results: What Investors Should Watch on May 1 - Stock Titan

Wed, 16 Apr 2025
Lobbying Update: $40,000 of CERUS CORPORATION lobbying was just disclosed - Nasdaq

Sat, 12 Apr 2025
After losing 21% in the past year, Cerus Corporation (NASDAQ:CERS) institutional owners must be relieved by the recent gain - simplywall.st

Mon, 31 Mar 2025
Cerus stock touches 52-week low at $1.37 amid market challenges - Investing.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 186 (M)
Shares Float 158 (M)
Held by Insiders 3.2 (%)
Held by Institutions 76.3 (%)
Shares Short 10,240 (K)
Shares Short P.Month 9,310 (K)
Stock Financials
EPS -0.11
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.3
Profit Margin -11.7 %
Operating Margin -2.9 %
Return on Assets (ttm) -4.5 %
Return on Equity (ttm) -38 %
Qtrly Rev. Growth 8.6 %
Gross Profit (p.s.) 0.53
Sales Per Share 0.97
EBITDA (p.s.) -0.07
Qtrly Earnings Growth 0 %
Operating Cash Flow 11 (M)
Levered Free Cash Flow 11 (M)
Stock Valuations
PE Ratio -12.46
PEG Ratio 0
Price to Book value 4.56
Price to Sales 1.41
Price to Cash Flow 22.4
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android